However, adjuvant humanized monoclonal antibody directed against HER2 (trastuzumab) or HER2-targeted tyrosine kinase inhibitors (e.g. Lapatinib) have dramatically improved survival of breast cancer patients with HER2 overexpression (HER2+), compared with patients without such overexpression (HER2-)6. This evidence concerns the gene ERBB2 and breast cancer.